(Q37799046)

23 August 2017

Status of tumor markers in epithelial ovarian cancer has there been any progress? A review (English)

1 reference

23 August 2017

1 reference

Nader Husseinzadeh

1

1 reference

PubMed ID

20934205

23 August 2017

language of work or name

English

0 references

publication date

14 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

120

1 reference

23 August 2017

152-157

1 reference

23 August 2017

1

1 reference

23 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Status of Tumor Markers in Ovarian Cancer Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Use of proteomic patterns in serum to identify ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

A test before its time? FDA stalls distribution process of proteomic test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Importance of communication between producers and consumers of publicly available experimental data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

New tumor markers: CA125 and beyond.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Blood and urine markers for ovarian cancer: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Prospective study of serum CA-125 levels as markers of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Plasma bikunin as a favorable prognostic factor in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

C-reactive protein: ligands, receptors and role in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Serum C-reactive protein in the differential diagnosis of ovarian masses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Serum protein markers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Characterization of serum biomarkers for detection of early stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Diagnostic markers for early detection of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Validation of serum biomarkers for detection of early-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Osteopontin as a potential diagnostic biomarker for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

The functional and clinical roles of osteopontin in cancer and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Potential markers that complement expression of CA125 in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.09.002

10.1016/J.YGYNO.2010.09.002

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20934205